{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:36:17Z","timestamp":1761237377925},"reference-count":63,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2006,12,1]]},"DOI":"10.1185\/030079906x154114","type":"journal-article","created":{"date-parts":[[2006,12,2]],"date-time":"2006-12-02T16:02:48Z","timestamp":1165075368000},"page":"2603-2612","source":"Crossref","is-referenced-by-count":16,"title":["Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance"],"prefix":"10.1185","volume":"22","author":[{"given":"Marie-Pierre de","family":"B\u00e9thune","sequence":"first","affiliation":[{"name":"Tibotec BVBA, Mechelen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Hertogs","sequence":"additional","affiliation":[{"name":"Tibotec BVBA, Mechelen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2006,11,29]]},"reference":[{"key":"CIT0001","unstructured":"US NIH Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents \u2013 May 4, 2006 [online]. Available from http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf [Last accessed 14 August 2006]"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.04.035"},{"key":"CIT0003","unstructured":"Cheung PK, Wynhoven B, Harrigan PR. 2004: which HIV-1 drug resistance mutations are common in clinical practice? AIDS Rev 2004;6: 107\u201316"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2005.21.343"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.20051"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200006160-00018"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1086\/432916"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.5.521"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000171414.99409.fb"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000131310.52526.c7"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1086\/430387"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1086\/378301"},{"key":"CIT0013","first-page":"445","volume":"28","author":"Ammassari A","year":"2001","journal-title":"AdICONA Study Group. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr"},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/135965350400900514","volume":"9","author":"Pillay D","year":"2004","journal-title":"Antivir Ther"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2003.12.002"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1080\/03008870310009597"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.8.5087-5094.1995"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1126\/science.7824947"},{"key":"CIT0019","unstructured":"Lal RB, Chakrabarti S, Yang C. Impact of genetic diversity of HIV-1 on diagnosis, antiretroviral therapy and vaccine development. Indian J Med Res 2005;121: 287\u2013314"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1007\/s001090050257"},{"key":"CIT0021","first-page":"229","volume":"275","author":"Keulen W","year":"1997","journal-title":"Science"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg079"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00777.x"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1007\/BF02253518"},{"key":"CIT0025","first-page":"41","volume":"49","author":"Clavel F","year":"2000","journal-title":"HIV drug resistance and viral fitness. Adv Pharmacol"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043382404"},{"key":"CIT0027","unstructured":"Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus study. 11th Conference on Retroviruses and Opportunistic Infections; February 8\u201311, 2004; San Francisco, California, USA. Abstract 52"},{"key":"CIT0028","unstructured":"Ruane P, Luber A, Akil B, et al. Factors influencing selection of K65R mutation among patients receiving tenofovir (TDF) containing regimens. 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13\u201316, 2003; Paris, France. Abstract 582"},{"key":"CIT0029","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350300800605","volume":"8","author":"Gallant JE","year":"2003","journal-title":"Antivir Ther"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440610.x"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363080-00004"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.9.7632-7637.1998"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1038\/nsb0795-523"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1021\/bi00029a002"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2004.08.010"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.50.31957"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.2174\/0929867013371842"},{"key":"CIT0039","unstructured":"Cohen C, Steinhart CR, Ward DJ, et al. 48-week durable efficacy and safety results of TMC125 in HIV patients with NNRTI and PI resistance-study TMC125-C223. 12th Annual Conference of the British HIV Association (BHIVA); March 29\u2013April 1, 2006; Brighton, UK. Abstract 2"},{"key":"CIT0040","unstructured":"de Bethune M-P, Andries K, Azijn H, et al. TMC278, a new potent NNRTI, with an increased barrier to resistance and favourable pharmacokinetic profile. 12th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA, 22\u201325 February 2005. Abstract S56"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.12.3218"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.1058"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009080-00009"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2093-2099.2000"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012354"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200403260-00008"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3123-3129.2003"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1021\/jm049560p"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.21.12012-12021.2004"},{"key":"CIT0050","unstructured":"Dierynck I, Keuleers IM, De Wit M, et al. Kinetic characterization of the potent activity of TMC114 on wild-type HIV-1 protease. 14th International HIV Drug Resistance Workshop; June 7\u201311, 2005; Quebec City, Quebec, Canada. Abstract 64"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1002\/jmr.655"},{"key":"CIT0052","unstructured":"Muzammil S, Kang LW, Armstrong AA, et al. Binding energetics analysis shows a unique response of tipranavir to HIV-1 protease mutations associated with drug resistance. 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24\u201327, 2005; Rio de Janeiro, Brazil. Abstract WePp0103"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(98)00098-5"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.3.1349-1358.2002"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1110\/ps.0206402"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1021\/jo049156y"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2314-2321.2005"},{"key":"CIT0058","unstructured":"Staes M, Van Craenenbroeck E, Vermeiren H, et al. Analyses of susceptibility and cross-resistance between TMC114 and other protease inhibitors among > 56,000 routine samples, using linear regression model-based fold change predictions. Antivir Ther 2006;11:S33, Abstract 28"},{"key":"CIT0059","unstructured":"De Meyer S, Cao-Van K, Lathouwers E, et al. Phenotypic and genotypic profiling of TMC114, lopinavir and tipranavir against PI-resistant HIV-1 clinical isolates. 4th European HIV Drug Resistance Workshop; March 29\u201331, 2006; Monte Carlo, Cote d\u2019Azur, Monaco. Abstract 42"},{"key":"CIT0060","unstructured":"De Meyer S, Azjin H, Fransen E, et al. The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors. Antivir Ther 2006:11:S24, Abstract 19"},{"key":"CIT0061","unstructured":"Katlama C, Carvalho MTM, Cooper D, et al. TMC114\/r outperforms investigator-selected PI(s) in 3-class-experienced patients: Week 24 primary efficacy analysis of POWER 1 (TMC114-c213). 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24\u201327, 2005; Rio de Janeiro, Brazil. Abstract WeOaLB0102"},{"key":"CIT0062","unstructured":"Wilkin T, Haubrich R, Steinhart CR, et al. TMC114\/r superior to standard of care in 3-class-experienced patients: 24-wk primary analysis of the POWER 2 study (C202). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16\u201319, 2005; Washington DC, USA. Abstract H\u2013413"},{"key":"CIT0063","unstructured":"De Meyer S, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3. Antivir Ther 2006:11:S83, Abstract 73"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079906X154114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T21:48:08Z","timestamp":1683668888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079906X154114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,29]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12,1]]}},"alternative-id":["10.1185\/030079906X154114"],"URL":"https:\/\/doi.org\/10.1185\/030079906x154114","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,29]]}}}